OPRL1

Across TCGA pan-cancer cohorts, OPRL1 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated OPRL1 data layer compared with 22 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher OPRL1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated OPRL1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

OV, ESCA, and STAD are the cancer types where OPRL1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	II,III,IV	0.222	0.541	.038	18	view →
ESCA	OS	Median	II,III,IV	0.130	0.703	<.001	18	view →
STAD	DFS	Median	All	0.279	0.713	.009	15	view →
UCEC	DFS	Median	All	1.000	0.632	.016	10	view →
LIHC	DFS	Median	All	0.121	0.555	.007	9	view →
SKCM	DFS	Median	III,IV	0.891	0.459	.015	8	view →
PRAD	DFS	Median	All	0.617	0.886	.013	6	view →
GBM	OS	Median	All	0.075	0.416	.011	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

OPRL1–OV (DFS)

Open the OV breakdown →